In this episode of the Vital Health Podcast, host Duane Schulthess speaks with two experts on reimbursement-facing evidence questions for accelerated oncology approvals at ISPOR Europe 2025 in Glasgow, Scotland:


Anja Schiel:Senior Advisor, Norwegian Medical Products Agency


Niklas Hedberg: Chief Pharmacist at The Dental and Pharmaceutical Benefits Agency (TLV)

They unpack why results that are strong inside a clinical trial can be harder to apply to real-world national populations, how decision-makers weigh patient-relevant outcomes and uncertainty at the time of access decisions, and what risk management can look like when early approvals require follow-up evidence and potential reassessment.

Key Topics:


Trial Generalizability: Selection in trials, real-world populations, and health system variation.


Reimbursement Evidence: Patient-relevant outcomes, absolute versus comparative benefit, small-sample challenges.


Conditional Approval: Evidence at authorization, reassessment expectations, withdrawal, and restriction risk.


Risk Tradeoffs: Approving too early versus delaying access, urgency in progressive disease, and equity constraints.


Adaptive Follow-up: Real-world evidence plans, managed entry approaches, learning while treating.

Opinions expressed are those of the speakers. This podcast was supported by Merck Sharp & Dohme as part of the APACE project, in collaboration with GlaxoSmithKline and AstraZeneca.

In this episode of the Vital Health Podcast, host <a href="https://www.linkedin.com/in/duane-schulthess-66ba39b7/">Duane Schulthess</a> speaks with two experts on reimbursement-facing evidence questions for accelerated oncology approvals at ISPOR Europe 2025 in Glasgow, Scotland:
<ul data-start="5108" data-end="5337">
<li data-start="5108" data-end="5246">
<a href="https://www.linkedin.com/in/anjaschiel/?originalSubdomain=no">Anja Schiel:</a> Senior Advisor, <a href="https://www.linkedin.com/company/direktoratetformedisinskeprodukter/">Norwegian Medical Products Agency</a>
</li>
<li data-start="5247" data-end="5337">
<a href="https://www.linkedin.com/in/niklas-hedberg-3947231/">Niklas Hedberg:</a> Chief Pharmacist at <a href="https://www.linkedin.com/company/tlv-the-dental-and-pharmaceutical-benefits-agency/">The Dental and Pharmaceutical Benefits Agency (TLV)</a>
</li>
</ul>
They unpack why results that are strong inside a clinical trial can be harder to apply to real-world national populations, how decision-makers weigh patient-relevant outcomes and uncertainty at the time of access decisions, and what risk management can look like when early approvals require follow-up evidence and potential reassessment.
Key Topics:
<ul data-start="5695" data-end="6250">
<li data-start="5695" data-end="5794">
Trial Generalizability: Selection in trials, real-world populations, and health system variation.
</li>
<li data-start="5795" data-end="5913">
Reimbursement Evidence: Patient-relevant outcomes, absolute versus comparative benefit, small-sample challenges.
</li>
<li data-start="5914" data-end="6028">
Conditional Approval: Evidence at authorization, reassessment expectations, withdrawal, and restriction risk.
</li>
<li data-start="6029" data-end="6146">
Risk Tradeoffs: Approving too early versus delaying access, urgency in progressive disease, and equity constraints.
</li>
<li data-start="6147" data-end="6250">
Adaptive Follow-up: Real-world evidence plans, managed entry approaches, learning while treating.
</li>
</ul>
Opinions expressed are those of the speakers. This podcast was supported by Merck Sharp &amp; Dohme as part of the APACE project, in collaboration with GlaxoSmithKline and AstraZeneca.

Duane Schulthess is the CEO of Vital Transformation, host and producer of Vital Health Podcast.  Vital Transformation understands the implications of new medical procedures, technologies and regulations. We measure their impact upon treatment pathways and the biopharma innovation ecosystem in collaboration with health care professionals, researchers, and regulators. Through our web platform and client network, we are able to communicate our findings with international decision makers and stakeholders.

Duane Schulthess is the CEO of Vital Transformation, host and producer of Vital Health Podcast.  Vital Transformation understands the implications of new medical procedures, technologies and regulations. We measure their impact upon treatment pathways and the biopharma innovation ecosystem in collaboration with health care professionals, researchers, and regulators. Through our web platform and client network, we are able to communicate our findings with international decision makers and stakeholders.

Duane Schulthess, Managing Director of Vital Tran…

Vital Health Podcast

Anja Schiel & Nicholas Hedberg: Accelerated Approvals, Evidence Gaps, and Reimbursement Risk

In this episode of the Vital Health Podcast, host Duane Schulthess speaks with three experts on accelerated patient access to cancer medicines at ISPOR Europe 2025 in Glasgow, Scotland:
Martina Garau: Director at Office of Health Economics
Bettina Ryll: Founder at MPNEurope
Kathleen Grieve: Director - European Public Policy, Access, Pricing and Affordability Lead at MSD Europe

They explore why accelerated access matters when evidence is still emerging, how the APACE framework proposes a structured path from eligibility through reassessment, what it could take to reduce fragmentation across national HTA and reimbursement processes, and why pragmatic pilots and agreed data expectations are central to learning while treating.

Key Topics:
Accelerated Access: Urgency in life-threatening cancer, uneven uptake across countries, and patient time sensitivity.
APACE Framework: Eligibility screening, initial assessment, temporary reimbursement, reassessment, and exit decisions.
National Alignment: EU-level assessment versus country decisions, shared principles, local implementation limits.
Evidence Uncertainty: Early evidence tradeoffs, real-world data needs, and affordability pressure under uncertainty.
Getting Started: Pilot use cases, coalition of the willing, dynamic evidence expectations over time.

Opinions expressed are those of the speakers. This podcast was supported by Merck Sharp & Dohme as part of the APACE project, in collaboration with GlaxoSmithKline and AstraZeneca.

In this episode of the Vital Health Podcast, host <a href="https://www.linkedin.com/in/duane-schulthess-66ba39b7/">Duane Schulthess</a> speaks with three experts on accelerated patient access to cancer medicines at ISPOR Europe 2025 in Glasgow, Scotland:
<ul>
<li><a href="https://www.linkedin.com/in/martina-garau-806b0b2a/?originalSubdomain=uk">Martina Garau:</a> Director at <a href="https://www.linkedin.com/company/office-of-health-economics/">Office of Health Economics</a></li>
<li><a href="https://www.linkedin.com/in/bettinaryll/?originalSubdomain=se">Bettina Ryll:</a> Founder at <a href="https://www.linkedin.com/company/mpneurope/">MPNEurope</a></li>
<li><a href="https://www.linkedin.com/in/kathleen-grieve-7453a69/?originalSubdomain=be">Kathleen Grieve:</a> Director - European Public Policy, Access, Pricing and Affordability Lead at <a href="https://www.linkedin.com/company/msdeurope/">MSD Europe</a></li>
</ul>
They explore why accelerated access matters when evidence is still emerging, how the APACE framework proposes a structured path from eligibility through reassessment, what it could take to reduce fragmentation across national HTA and reimbursement processes, and why pragmatic pilots and agreed data expectations are central to learning while treating.
Key Topics:
<ul>
<li>Accelerated Access: Urgency in life-threatening cancer, uneven uptake across countries, and patient time sensitivity.</li>
<li>APACE Framework: Eligibility screening, initial assessment, temporary reimbursement, reassessment, and exit decisions.</li>
<li>National Alignment: EU-level assessment versus country decisions, shared principles, local implementation limits.</li>
<li>Evidence Uncertainty: Early evidence tradeoffs, real-world data needs, and affordability pressure under uncertainty.</li>
<li>Getting Started: Pilot use cases, coalition of the willing, dynamic evidence expectations over time.</li>
</ul>
Opinions expressed are those of the speakers.&nbsp;This podcast was supported by Merck Sharp &amp; Dohme as part of the APACE project, in collaboration with GlaxoSmithKline and AstraZeneca.

Kathleen Grieve, Martina Garau, & Bettina Ryll: Accelerating Patient Access To Cancer Medicines In Europe

In this special 2025 U.S. Policy Highlights edition of the Vital Health Podcast, we look back at our most important discussions on the Inflation Reduction Act (IRA) and its ripple effects across drug development, Medicare, and patient access. Over the past year, the biopharma industry and the broader healthcare system have undergone a period of rapid change as new rules surrounding drug pricing reshape how therapies are developed, financed, and delivered. In a landscape where policies are still being interpreted and adjusted, and where the long-term impact on innovation and access is far from certain, this episode serves as a year-end guide to what has changed and how to think about the road ahead.

Throughout 2025, we paired our research with a series of podcast episodes where host Duane Schulthess sat down with industry leaders. In this highlights episode, we revisit several of those conversations:
Donna Cryer: Advocacy, Drug Incentives & Research Crisis
Barbara McAneny, Rafael Fonseca, and Steve Potts: Protecting Patients Amid the IRA
Kirsten Axelsen: Part D Shift, IRA Penalties, and Access Risks

Key Topics:
Pill Penalty: How the shorter negotiation window for small molecule medicines relative to biologics is changing the calculus for pursuing oral therapies in areas such as cardiovascular disease, neurodegeneration, and other chronic conditions.
Part D Redesign: Why moving more liability to plans is driving new premium and coverage tradeoffs, influencing which products stay on formularies, and raising questions about access in rural and underserved areas.
Early Stage Investment: What our data suggest about the pullback in trial starts and funding for projects most exposed to IRA mechanics, and how that is influencing company formation, licensing strategies, and pipeline mix.
PBMs, Vertical Integration, & Biosimilars: How consolidated intermediaries and payer-owned biosimilar strategies interact with IRA price setting, rebate flows, and the outlook for generic and biosimilar competition.
Patient Advocacy & Real World Impact: What older adults, cancer patients, and rare disease communities are already experiencing as coverage rules change, cost-sharing is redesigned, and uncertainty grows around long-term treatment availability.
Policy Paths Forward: Ideas from our guests for adjusting timelines, refining negotiation rules, and protecting incentives for follow-on and orphan indications while still improving affordability for patients.

Opinions expressed are those of the speakers.

In this special 2025 U.S. Policy Highlights edition of the Vital Health Podcast, we look back at our most important discussions on the Inflation Reduction Act (IRA) and its ripple effects across drug development, Medicare, and patient access. Over the past year, the biopharma industry and the broader healthcare system have undergone a period of rapid change as new rules surrounding drug pricing reshape how therapies are developed, financed, and delivered. In a landscape where policies are still being interpreted and adjusted, and where the long-term impact on innovation and access is far from certain, this episode serves as a year-end guide to what has changed and how to think about the road ahead.
Throughout 2025, we paired our research with a series of podcast episodes where host Duane Schulthess sat down with industry leaders. In this highlights episode, we revisit several of those conversations:
<ul>
<li>Donna Cryer: Advocacy, Drug Incentives &amp; Research Crisis</li>
<li>Barbara McAneny, Rafael Fonseca, and Steve Potts: Protecting Patients Amid the IRA</li>
<li>Kirsten Axelsen: Part D Shift, IRA Penalties, and Access Risks</li>
</ul>
Key Topics:
<ul>
<li>Pill Penalty: How the shorter negotiation window for small molecule medicines relative to biologics is changing the calculus for pursuing oral therapies in areas such as cardiovascular disease, neurodegeneration, and other chronic conditions.</li>
<li>Part D Redesign: Why moving more liability to plans is driving new premium and coverage tradeoffs, influencing which products stay on formularies, and raising questions about access in rural and underserved areas.</li>
<li>Early Stage Investment: What our data suggest about the pullback in trial starts and funding for projects most exposed to IRA mechanics, and how that is influencing company formation, licensing strategies, and pipeline mix.</li>
<li>PBMs, Vertical Integration, &amp; Biosimilars: How consolidated intermediaries and payer-owned biosimilar strategies interact with IRA price setting, rebate flows, and the outlook for generic and biosimilar competition.</li>
<li>Patient Advocacy &amp; Real World Impact: What older adults, cancer patients, and rare disease communities are already experiencing as coverage rules change, cost-sharing is redesigned, and uncertainty grows around long-term treatment availability.</li>
<li>Policy Paths Forward: Ideas from our guests for adjusting timelines, refining negotiation rules, and protecting incentives for follow-on and orphan indications while still improving affordability for patients.</li>
</ul>
Opinions expressed are those of the speakers.

2025 US Policy Highlights - Inflation Reduction Act (IRA) Part 2

In this special 2025 U.S. Policy Highlights edition of the Vital Health Podcast, we look back at our most important discussions on Most Favored Nation (MFN) drug pricing and its knock-on effects for jobs, state budgets, and the generic supply chain. Over the past year, proposals to link U.S. prices to those in other countries have collided with inflation pressures, tariff debates, and reshoring efforts, creating new uncertainty for manufacturers, payers, and policymakers. In an environment where expectations about future returns are shifting, and the rules of the game are still being defined, this episode is designed as a year-end guide to what MFN-style policies could mean in practice and how to think about the tradeoffs.

Throughout 2025, we our research on MFN-style reference pricing with a series of podcast episodes where host Duane Schulthess sat down with leaders across the generic, distribution, and policy landscape. In this highlights episode, we revisit several of those conversations:
Kirsten Axelsen: Part D Shift, IRA Penalties, and Access Risks
Patrick Kelly: Inside the Generic Supply Chain Squeeze
John Murphy: Generics, Biosimilars, and U.S. Policy
VT’s Grumpies (Harry Bowen, Joe Hammang) Talk MFN

Key Topics:
MFN Mechanics Explained: How tying U.S. prices to the lowest GDP-adjusted price in a reference basket translates into steep cuts for top-spend medicines in Medicare Parts B and D and shapes expectations across commercial and Medicaid contracts.
Jobs, Earnings, & State Budgets: What our modeling suggests about potential impacts on employment, earnings, and tax revenue under MFN-style reference pricing, and how those effects concentrate in R&D-intensive regions and manufacturing hubs.
Spillovers Into Medicaid, 340B, & ASP: Why MFN in Medicare does not stay in Medicare, how Medicaid best price and 340B ceilings pull discounts across programs, and what lower ASP add-ons could mean for hospital and community oncology margins.
Generics, Shortages, & Tariffs: How razor-thin margins for sterile injectables and generic manufacturers interact with purchaser consolidation, tariff shocks, and price referencing, raising the risk of exits, inventory write-downs, and persistent shortages.
Global Competition & Offshoring: How aggressive reference pricing can accelerate shifts in trials, licensing, and high-value manufacturing to countries that offer more predictable returns, and what that implies for long-run U.S. competitiveness.
Alternatives To MFN: Ideas from our guests on value-based approaches, targeted incentives, and other tools that can improve affordability without hollowing out domestic capacity, innovation, and resilience in the generic and biosimilar supply chain.

Opinions expressed are those of the speakers.

In this special 2025 U.S. Policy Highlights edition of the Vital Health Podcast, we look back at our most important discussions on Most Favored Nation (MFN) drug pricing and its knock-on effects for jobs, state budgets, and the generic supply chain. Over the past year, proposals to link U.S. prices to those in other countries have collided with inflation pressures, tariff debates, and reshoring efforts, creating new uncertainty for manufacturers, payers, and policymakers. In an environment where expectations about future returns are shifting, and the rules of the game are still being defined, this episode is designed as a year-end guide to what MFN-style policies could mean in practice and how to think about the tradeoffs.
Throughout 2025, we our research on MFN-style reference pricing with a series of podcast episodes where host Duane Schulthess sat down with leaders across the generic, distribution, and policy landscape. In this highlights episode, we revisit several of those conversations:
<ul>
<li>Kirsten Axelsen: Part D Shift, IRA Penalties, and Access Risks</li>
<li>Patrick Kelly: Inside the Generic Supply Chain Squeeze</li>
<li>John Murphy: Generics, Biosimilars, and U.S. Policy</li>
<li>VT&rsquo;s Grumpies (Harry Bowen, Joe Hammang) Talk MFN</li>
</ul>
Key Topics:
<ul>
<li>MFN Mechanics Explained: How tying U.S. prices to the lowest GDP-adjusted price in a reference basket translates into steep cuts for top-spend medicines in Medicare Parts B and D and shapes expectations across commercial and Medicaid contracts.</li>
<li>Jobs, Earnings, &amp; State Budgets: What our modeling suggests about potential impacts on employment, earnings, and tax revenue under MFN-style reference pricing, and how those effects concentrate in R&amp;D-intensive regions and manufacturing hubs.</li>
<li>Spillovers Into Medicaid, 340B, &amp; ASP: Why MFN in Medicare does not stay in Medicare, how Medicaid best price and 340B ceilings pull discounts across programs, and what lower ASP add-ons could mean for hospital and community oncology margins.</li>
<li>Generics, Shortages, &amp; Tariffs: How razor-thin margins for sterile injectables and generic manufacturers interact with purchaser consolidation, tariff shocks, and price referencing, raising the risk of exits, inventory write-downs, and persistent shortages.</li>
<li>Global Competition &amp; Offshoring: How aggressive reference pricing can accelerate shifts in trials, licensing, and high-value manufacturing to countries that offer more predictable returns, and what that implies for long-run U.S. competitiveness.</li>
<li>Alternatives To MFN: Ideas from our guests on value-based approaches, targeted incentives, and other tools that can improve affordability without hollowing out domestic capacity, innovation, and resilience in the generic and biosimilar supply chain.</li>
</ul>
Opinions expressed are those of the speakers.

Anja Schiel & Nicholas Hedberg: Accelerated Approvals, Evidence Gaps, and Reimbursement Risk

Vital Health Podcast

In 1 playlist(s)

Vital Health Podcast

Social links

Follow podcast

Recent clips